{"protocolSection":{"identificationModule":{"nctId":"NCT01017874","orgStudyIdInfo":{"id":"13021"},"secondaryIdInfos":[{"id":"H3E-CR-S131","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer","officialTitle":"A Randomized Ph 3 Study Comparing First-Line Pemetrexed/Cisplatin Followed by Gefitinib With Gefitinib Alone in East Asian Never Smoker or Light Ex-Smoker Patients With Locally Advanced or Metastatic Nonsquamous NSCLC"},"statusModule":{"statusVerifiedDate":"2015-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-11"},"primaryCompletionDateStruct":{"date":"2013-04","type":"ACTUAL"},"completionDateStruct":{"date":"2014-10","type":"ACTUAL"},"studyFirstSubmitDate":"2009-11-19","studyFirstSubmitQcDate":"2009-11-19","studyFirstPostDateStruct":{"date":"2009-11-23","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-02-21","resultsFirstSubmitQcDate":"2014-02-21","resultsFirstPostDateStruct":{"date":"2014-04-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-06-09","lastUpdatePostDateStruct":{"date":"2015-07-08","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants. Half of the participants will receive chemotherapy (pemetrexed/cisplatin) followed by an oral anti-cancer agent (gefitinib) and the other half of the participants will receive only the oral anti-cancer agent (gefitinib)."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":236,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed + Cisplatin + Gefitinib","type":"EXPERIMENTAL","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin","Drug: Gefitinib"]},{"label":"Gefitinib","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Gefitinib"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed","description":"500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.","armGroupLabels":["Pemetrexed + Cisplatin + Gefitinib"],"otherNames":["Alimta","LY231514"]},{"type":"DRUG","name":"Cisplatin","description":"75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles","armGroupLabels":["Pemetrexed + Cisplatin + Gefitinib"]},{"type":"DRUG","name":"Gefitinib","description":"250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy","armGroupLabels":["Pemetrexed + Cisplatin + Gefitinib"]},{"type":"DRUG","name":"Gefitinib","description":"250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy","armGroupLabels":["Gefitinib"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS)","description":"PFS was defined as the time from date of randomization to the objective disease progression or death due to any cause. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. Progressive disease (PD) was defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions. Participants who did not have a complete baseline disease assessment were censored at the date of randomization, regardless if PD was objectively determined or if participant died or if a participant was not known to have died or have objective PD at the data inclusion cutoff date. PFS was censored at the last complete objective progression-free disease assessment date.","timeFrame":"Randomization to the first date of measured PD or death up to 37.32 months"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS was the duration from randomization to the date of death from any cause. For participants who were not known to have died as of the data-inclusion cut-off date for a particular analysis, OS was censored at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date included adverse event date, lesion assessment date, visit date, and last known alive date).","timeFrame":"Randomization up to date of death from any cause up to 57.13 months"},{"measure":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]","description":"TRR was defined as the percentage of randomized participants having a best overall study response of CR or PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and the appearance of no new lesions.","timeFrame":"Randomization up to 37.52 months"},{"measure":"Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]","description":"DCR was defined as the percentage of randomized participants with overall response of CR, PR or SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all tumor lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared; SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD. PD defined as at least 20% increase in the sum of LD of target, lesions taking as reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions or progression of nontarget lesions.","timeFrame":"Randomization up to 37.52 months"},{"measure":"Time to Progressive Disease (TtPD)","description":"TtPD was defined as the time from randomization to the first date of objectively determined progressive disease (PD). For participants who were not known to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, or who had died without objective progression of disease, TtPD was censored at the date of the participant's last objective progression-free disease assessment prior to cut-off date.","timeFrame":"Randomization to the first date of measured PD up to 37.32 months"},{"measure":"Duration of Tumor Response","description":"The duration of a complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria was defined as the time from first objective status assessment of CR or PR to the first time of objective disease progression or death as a result of any cause. CR was defined as the disappearance of all tumor lesions. PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum of LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared. Participants who were not known to have died or had objective progression of disease as of the data-inclusion cut-off date were censored at the date of the participant's last complete objective progression-free disease assessment prior to that cut-off date.","timeFrame":"Date of initial response to the date of measured PD or death up to 34.43 months"},{"measure":"Time to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS)","description":"The LCSS data included participant ratings of 6 symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) and 3 summary items (overall symptom severity, interference with daily activities, and overall QoL). Participants recorded their ratings for each item, by placing a mark on a visual analog scale (VAS) that ranged from 0 millimeter (mm) (lower symptom burden, less interference with normal activity, or better QoL) to 100 mm (higher symptom burden, more interference with normal activity, or worse QoL). TWQ was evaluated from date of randomization to first date of worsening, defined as a half standard deviation change as determined from the corresponding baseline item score in the pooled treatment group. For participants not known to have worsened or who were lost to follow-up, TWQ was censored at date of the participant's last LCSS assessment.","timeFrame":"Every cycle while on-study therapy and at 3 months post last dose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological diagnosis of NSCLC with locally advanced or metastatic disease that is of non-squamous histology.\n* Participants must be \"light ex-smokers\" or \"never-smokers\".\n\n  * \"Light ex-smokers\" defined as having ceased smoking for greater than or equal to 5 years and not to have exceeded 10 pack-years.\n  * \"Never-smokers\" are defined as having smoked \\<100 cigarettes or equivalent during his/her lifetime.\n* Participants must be of East Asian ethnicity.\n* No prior systemic therapy for lung cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n* Presence of clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.\n* Any evidence of clinically active interstitial lung disease. Asymptomatic participants with chronic, stable, radiographic changes are eligible.\n* Participants whose Epidermal Growth Factor Receptor (EGFR) mutation status is known prior to study entry will be excluded. Participants in which EGFR mutation testing has not been performed, or whose EGFR mutation status is unknown or inconclusive at study entry are eligible.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kowloon","country":"Hong Kong","geoPoint":{"lat":22.31667,"lon":114.18333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Singapore","zip":"258499","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Incheon","zip":"405-760","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seoul","zip":"110-744","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kuei Shan Hsiang","zip":"33305","country":"Taiwan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Liouying/Tainan","zip":"736","country":"Taiwan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Puzih City","zip":"613","country":"Taiwan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taichung","zip":"407","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chiang Mai","zip":"50200","country":"Thailand","geoPoint":{"lat":18.79038,"lon":98.98468}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hat Yai","zip":"90110","country":"Thailand","geoPoint":{"lat":7.00836,"lon":100.47668}}]},"referencesModule":{"references":[{"pmid":"26725183","type":"DERIVED","citation":"Yang JC, Srimuninnimit V, Ahn MJ, Lin CC, Kim SW, Tsai CM, Mok T, Orlando M, Puri T, Wang X, Park K. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. J Thorac Oncol. 2016 Mar;11(3):370-9. doi: 10.1016/j.jtho.2015.11.008. Epub 2015 Dec 25."},{"pmid":"26511807","type":"DERIVED","citation":"Kang JH, Ahn MJ, Kim DW, Cho EK, Kim JH, Shin SW, Wang X, Kim JS, Orlando M, Park K. Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. Cancer Res Treat. 2016 Apr;48(2):458-64. doi: 10.4143/crt.2015.135. Epub 2015 Oct 14."},{"pmid":"24953333","type":"DERIVED","citation":"Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. Eur J Cancer. 2014 Sep;50(13):2219-30. doi: 10.1016/j.ejca.2014.05.011. Epub 2014 Jun 18."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants who died or continued on study but discontinued receiving study drug were considered to be completed.","groups":[{"id":"FG000","title":"Pemetrexed + Cisplatin + Gefitinib","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nGefitinib: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, as maintenance therapy in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy"},{"id":"FG001","title":"Gefitinib","description":"Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"118"},{"groupId":"FG001","numSubjects":"118"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"118"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"88"},{"groupId":"FG001","numSubjects":"92"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"26"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"Sponsor decision","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"Pemetrexed + Cisplatin + Gefitinib","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nGefitinib: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, as maintenance therapy in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy"},{"id":"BG001","title":"Gefitinib","description":"Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"236"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58.53","spread":"10.730"},{"groupId":"BG001","value":"59.36","spread":"10.672"},{"groupId":"BG002","value":"58.95","spread":"10.686"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"177"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"59"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participant","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"236"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Hong Kong","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"10"}]}]},{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"67"}]}]},{"title":"Thailand","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"43"}]}]},{"title":"Singapore","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]},{"title":"Korea, Republic of","categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"114"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS)","description":"PFS was defined as the time from date of randomization to the objective disease progression or death due to any cause. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. Progressive disease (PD) was defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions. Participants who did not have a complete baseline disease assessment were censored at the date of randomization, regardless if PD was objectively determined or if participant died or if a participant was not known to have died or have objective PD at the data inclusion cutoff date. PFS was censored at the last complete objective progression-free disease assessment date.","populationDescription":"Intent-to-treat (ITT) population: All data from all randomized participants according to the treatment they were assigned. Censored participants: Pemetrexed+Cisplatin+Gefitinib=32, Gefitinib=22.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to the first date of measured PD or death up to 37.32 months","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin + Gefitinib","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nGefitinib: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, as maintenance therapy in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy"},{"id":"OG001","title":"Gefitinib","description":"Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"118"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.38","lowerLimit":"6.44","upperLimit":"11.14"},{"groupId":"OG001","value":"9.63","lowerLimit":"6.74","upperLimit":"11.10"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.217","statisticalMethod":"Wilcoxon (Mann-Whitney)","paramType":"Hazard Ratio (HR)","paramValue":"0.85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"1.13"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was the duration from randomization to the date of death from any cause. For participants who were not known to have died as of the data-inclusion cut-off date for a particular analysis, OS was censored at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date included adverse event date, lesion assessment date, visit date, and last known alive date).","populationDescription":"ITT population: All data from all randomized participants according to the treatment they were assigned.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization up to date of death from any cause up to 57.13 months","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin + Gefitinib","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nGefitinib: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, as maintenance therapy in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy"},{"id":"OG001","title":"Gefitinib","description":"Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"118"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.87","lowerLimit":"20.76","upperLimit":"35.12"},{"groupId":"OG001","value":"27.86","lowerLimit":"21.26","upperLimit":"31.36"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.788","statisticalMethod":"Wilcoxon (Mann-Whitney)","paramType":"Hazard Ratio (HR)","paramValue":"0.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.68","ciUpperLimit":"1.31"}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]","description":"TRR was defined as the percentage of randomized participants having a best overall study response of CR or PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and the appearance of no new lesions.","populationDescription":"Intent-to-treat (ITT) population: All data from all randomized participants according to the treatment they were assigned.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Randomization up to 37.52 months","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin + Gefitinib","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nGefitinib: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, as maintenance therapy in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy"},{"id":"OG001","title":"Gefitinib","description":"Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"118"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.5","lowerLimit":"32.5","upperLimit":"51.0"},{"groupId":"OG001","value":"47.5","lowerLimit":"38.2","upperLimit":"56.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]","description":"DCR was defined as the percentage of randomized participants with overall response of CR, PR or SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all tumor lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared; SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD. PD defined as at least 20% increase in the sum of LD of target, lesions taking as reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions or progression of nontarget lesions.","populationDescription":"Intent-to-treat (ITT) population: All data from all randomized participants according to the treatment they were assigned.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Randomization up to 37.52 months","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin + Gefitinib","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nGefitinib: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, as maintenance therapy in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy"},{"id":"OG001","title":"Gefitinib","description":"Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"118"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","lowerLimit":"62.1","upperLimit":"79.2"},{"groupId":"OG001","value":"64.4","lowerLimit":"55.1","upperLimit":"73.0"}]}]}]},{"type":"SECONDARY","title":"Time to Progressive Disease (TtPD)","description":"TtPD was defined as the time from randomization to the first date of objectively determined progressive disease (PD). For participants who were not known to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, or who had died without objective progression of disease, TtPD was censored at the date of the participant's last objective progression-free disease assessment prior to cut-off date.","populationDescription":"Intent-to-treat (ITT) population: All data from all randomized participants according to the treatment they were assigned. Censored participants: Pemetrexed + Cisplatin + Gefitinib (G) =37, G=26.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to the first date of measured PD up to 37.32 months","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin + Gefitinib","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nGefitinib: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, as maintenance therapy in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy"},{"id":"OG001","title":"Gefitinib","description":"Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"118"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.61","lowerLimit":"6.60","upperLimit":"11.20"},{"groupId":"OG001","value":"9.69","lowerLimit":"6.87","upperLimit":"11.20"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.252","statisticalMethod":"Wilcoxon (Mann-Whitney)","paramType":"Hazard Ratio (HR)","paramValue":"0.85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"1.14"}]},{"type":"SECONDARY","title":"Duration of Tumor Response","description":"The duration of a complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria was defined as the time from first objective status assessment of CR or PR to the first time of objective disease progression or death as a result of any cause. CR was defined as the disappearance of all tumor lesions. PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum of LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared. Participants who were not known to have died or had objective progression of disease as of the data-inclusion cut-off date were censored at the date of the participant's last complete objective progression-free disease assessment prior to that cut-off date.","populationDescription":"A subset of the Intent-to-treat (ITT) population: All data from all randomized participants according to the treatment they were assigned who had confirmed CR or PR. Pemetrexed + Cisplatin + Gefitinib= 19, Gefitinib= 9.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Date of initial response to the date of measured PD or death up to 34.43 months","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin + Gefitinib","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nGefitinib: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, as maintenance therapy in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy"},{"id":"OG001","title":"Gefitinib","description":"Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.09","lowerLimit":"7.16","upperLimit":"22.11"},{"groupId":"OG001","value":"11.93","lowerLimit":"9.63","upperLimit":"14.09"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.952","statisticalMethod":"Wilcoxon (Mann-Whitney)","paramType":"Hazard Ratio (HR)","paramValue":"0.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.53","ciUpperLimit":"1.32"}]},{"type":"SECONDARY","title":"Time to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS)","description":"The LCSS data included participant ratings of 6 symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) and 3 summary items (overall symptom severity, interference with daily activities, and overall QoL). Participants recorded their ratings for each item, by placing a mark on a visual analog scale (VAS) that ranged from 0 millimeter (mm) (lower symptom burden, less interference with normal activity, or better QoL) to 100 mm (higher symptom burden, more interference with normal activity, or worse QoL). TWQ was evaluated from date of randomization to first date of worsening, defined as a half standard deviation change as determined from the corresponding baseline item score in the pooled treatment group. For participants not known to have worsened or who were lost to follow-up, TWQ was censored at date of the participant's last LCSS assessment.","populationDescription":"Participants who received at least 1 dose of study treatment and had LCSS data available. Participants censored (Pemetrexed + Cisplatin + Gefitinib, Gefitinib): Loss of appetite (33,59), Fatigue (42,54), Cough (52,65), Dyspnea (51,66), Hemoptysis (69,74), Pain (48,67), Overall symptoms (52,63), Interference (42,59), Overall QoL (51,51).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"Every cycle while on-study therapy and at 3 months post last dose","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin + Gefitinib","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nGefitinib: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, as maintenance therapy in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy"},{"id":"OG001","title":"Gefitinib","description":"Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"109"}]}],"classes":[{"title":"Loss of appetite","categories":[{"measurements":[{"groupId":"OG000","value":"2.99","lowerLimit":"1.71","upperLimit":"3.68"},{"groupId":"OG001","value":"7.95","lowerLimit":"4.90","upperLimit":"NA","comment":"upper bound not generated due to small sample size"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"4.83","lowerLimit":"2.92","upperLimit":"6.83"},{"groupId":"OG001","value":"7.29","lowerLimit":"3.75","upperLimit":"13.63"}]}]},{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"8.57","lowerLimit":"5.68","upperLimit":"10.94"},{"groupId":"OG001","value":"16.69","lowerLimit":"6.51","upperLimit":"NA","comment":"upper bound not generated due to small sample size"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"6.97","lowerLimit":"3.15","upperLimit":"15.44"},{"groupId":"OG001","value":"18.23","lowerLimit":"7.06","upperLimit":"NA","comment":"upper bound not generated due to small sample size"}]}]},{"title":"Hemoptysis","categories":[{"measurements":[{"groupId":"OG000","value":"19.45","lowerLimit":"9.89","upperLimit":"NA","comment":"upper bound not generated due to small sample size"},{"groupId":"OG001","value":"17.05","lowerLimit":"10.02","upperLimit":"NA","comment":"upper bound not generated due to small sample size"}]}]},{"title":"Pain","categories":[{"measurements":[{"groupId":"OG000","value":"6.44","lowerLimit":"2.92","upperLimit":"11.40"},{"groupId":"OG001","value":"15.57","lowerLimit":"9.95","upperLimit":"NA","comment":"upper bound not generated due to small sample size"}]}]},{"title":"Overall symptoms","categories":[{"measurements":[{"groupId":"OG000","value":"4.76","lowerLimit":"3.12","upperLimit":"12.81"},{"groupId":"OG001","value":"13.63","lowerLimit":"7.06","upperLimit":"NA","comment":"upper bound not generated due to small sample size"}]}]},{"title":"Interference","categories":[{"measurements":[{"groupId":"OG000","value":"4.50","lowerLimit":"3.02","upperLimit":"7.03"},{"groupId":"OG001","value":"8.34","lowerLimit":"4.90","upperLimit":"NA","comment":"upper bound not generated due to small sample size"}]}]},{"title":"Overall quality of life","categories":[{"measurements":[{"groupId":"OG000","value":"6.14","lowerLimit":"3.52","upperLimit":"12.78"},{"groupId":"OG001","value":"6.93","lowerLimit":"3.22","upperLimit":"13.63"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"Study-specific clinical outcomes due to progressive disease were not considered to be a serious adverse event (SAE) unless the investigator deemed it related to the use of the study drug.","eventGroups":[{"id":"EG000","title":"Pemetrexed + Cisplatin + Gefitinib","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nCisplatin: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles\n\nGefitinib: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, as maintenance therapy in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy","seriousNumAffected":35,"seriousNumAtRisk":114,"otherNumAffected":111,"otherNumAtRisk":114},{"id":"EG001","title":"Gefitinib","description":"Gefitinib: 250 mg administered orally once a day, every day of 21-day cycle, as a monotherapy","seriousNumAffected":32,"seriousNumAtRisk":118,"otherNumAffected":110,"otherNumAtRisk":118}],"seriousEvents":[{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Ulcerative keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Mallory-weiss syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":118}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Staphylococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Cervical cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Personality change","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Endometrial hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":84},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Pelvic prolapse","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":118}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":118}]},{"term":"Pulmonary alveolar haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Pulmonary artery thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":114},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":118}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":21,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":118}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":114},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":118}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":36,"numAtRisk":114},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":118}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":30,"numAtRisk":114},{"groupId":"EG001","numEvents":68,"numAffected":50,"numAtRisk":118}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":118}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":133,"numAffected":70,"numAtRisk":114},{"groupId":"EG001","numEvents":27,"numAffected":26,"numAtRisk":118}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":114},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":118}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":69,"numAffected":41,"numAtRisk":114},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":118}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":118}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":114},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":118}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":32,"numAtRisk":114},{"groupId":"EG001","numEvents":22,"numAffected":21,"numAtRisk":118}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":118}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":118}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":16,"numAffected":13,"numAtRisk":118}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":118}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":9,"numAtRisk":114},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":118}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":114},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":118}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":20,"numAtRisk":114},{"groupId":"EG001","numEvents":33,"numAffected":30,"numAtRisk":118}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":114},{"groupId":"EG001","numEvents":30,"numAffected":24,"numAtRisk":118}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":118}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":114},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":118}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":14,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":43,"numAtRisk":114},{"groupId":"EG001","numEvents":32,"numAffected":29,"numAtRisk":118}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":16,"numAffected":11,"numAtRisk":118}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":118}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":114},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":118}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":118}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":118}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":118}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":21,"numAtRisk":114},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":118}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":18,"numAtRisk":114},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":118}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":114},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":118}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":114},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":118}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":25,"numAtRisk":114},{"groupId":"EG001","numEvents":23,"numAffected":21,"numAtRisk":118}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":114},{"groupId":"EG001","numEvents":21,"numAffected":20,"numAtRisk":118}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":118}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":118}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":118}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":114},{"groupId":"EG001","numEvents":20,"numAffected":17,"numAtRisk":118}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":114},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":118}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":118}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":114},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":118}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":114},{"groupId":"EG001","numEvents":23,"numAffected":20,"numAtRisk":118}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":114},{"groupId":"EG001","numEvents":27,"numAffected":25,"numAtRisk":118}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":118}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":118}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":34,"numAtRisk":114},{"groupId":"EG001","numEvents":47,"numAffected":38,"numAtRisk":118}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":36,"numAtRisk":114},{"groupId":"EG001","numEvents":72,"numAffected":52,"numAtRisk":118}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":118}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":118}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":118}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Malaysia"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"},{"id":"D000077156","term":"Gefitinib"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D011799","term":"Quinazolines"}]}},"hasResults":true}